Compare Marqeta Inc (MQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Viatris Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.66B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 11.4× Marqeta Inc's market cap, and Viatris Inc pays a 2.91% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | VTRS | |
|---|---|---|
Market Cap | $1.66B | $18.95B |
Sector | Technology | Health |
52-Week High | $23.88 | $17.86 |
52-Week Low | $15.04 | $9.49 |
Enterprise Value | $970.76M | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive net cash flow of $86.42M in 2025. Recent developments include expansion of Google Wallet partnership and stablecoin card initiatives. Valuation metrics remain elevated with P/E of 180.89 and EV/EBITDA of 48.53 despite modest profitability margins.
MQ offers 26% upside to consensus price target of $19.00, supported by earnings estimate revisions and strategic partnerships. Key risks include high valuation multiples, competitive payment processing landscape, and the need to sustain recent profitability improvements. Institutional sentiment leans cautious with 59% hold ratings despite recent business momentum.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
